Source comparison
CJC-1295 No DAC vs With DAC: Protocol Comparison
Plasma Half-Life ~30 minutes 6–8 days No DAC variant requires multiple daily doses; DAC variant allows weekly dosing but higher cumulative exposure Dosing Frequency 2–3 times daily Once weekly No DAC mimics physiological GH pulsatility; DAC creates sustained e
This comparison does not assign a generated winner or score.
- Plasma Half-Life
- ~30 minutes
- 6–8 days
- No DAC variant requires multiple daily doses; DAC variant allows weekly dosing but higher cumulative exposure
- Dosing Frequency
- 2–3 times daily
- Once weekly
- No DAC mimics physiological GH pulsatility; DAC creates sustained elevation that may reduce receptor sensitivity
- GH Peak Magnitude
- High acute pulse (3–5× baseline)
- Moderate chronic elevation (1.5–2× baseline)
- No DAC produces sharper peaks aligned with endogenous secretion; DAC produces steady-state elevation
- Reconstitution Storage
- 28 days at 2–8°C
- Identical storage requirements post-reconstitution; both degrade rapidly if frozen or heated
- Receptor Desensitization Risk
- Low (pulsatile administration)
- Moderate to high (chronic elevation)
- No DAC's short half-life prevents prolonged receptor occupancy; DAC's sustained presence may blunt response over 8–12 weeks
- Research Application Suitability
- Acute GH response studies, pulsatility modeling
- Chronic GH elevation studies, long-term metabolic effects
- No DAC better for protocols requiring natural secretion patterns; DAC better for sustained intervention models